サンプル依頼リスト カート
  • English
  • Korean
表紙：多汗症治療の世界市場-2023年～2030年
市場調査レポート
商品コード
1347968

多汗症治療の世界市場-2023年～2030年

Global Hyperhidrosis Treatment Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 186 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
多汗症治療の世界市場-2023年～2030年
出版日: 2023年09月11日
発行: DataM Intelligence
ページ情報: 英文 186 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

概要

世界の多汗症治療機器市場は、2022年に4億5,020万米ドルに達し、2023年から2030年にかけてCAGR 4.5%で成長し、2030年には8億9,410万米ドルに達すると予測されています。

多汗症は、過剰で制御不能な発汗を特徴とする慢性疾患です。多汗症に伴うこの過剰な発汗は、汗腺が比較的集中しているため、通常、手、足、脇の下、鼠径部で最も活発です。治療法の承認数の増加、医薬品や局所治療薬の発売数の増加が市場成長の原動力となっています。

北米地域が市場シェアで大きな位置を占めると予想されます。ボツリヌス毒素Aセグメントが大きな市場シェアを占めています。発売数の増加と治療法の利点により、同分野が主導的な地位を占めると予想されます。

ダイナミクス

多汗症の有病率の上昇が市場成長を加速させる見込み

多汗症の有病率の増加が市場成長を促進すると予想されます。例えば、NIHに掲載された論文によると、米国人の3％が多汗症に罹患していると予想されています。疾患の特定の分類である原発性多汗症は、主に18歳から39歳の若年成人に発症し、遺伝的要素を持つことが多いです。

また、ドイツでは、多汗症の有病率は16*3％と予想されており、そのうちの6*1％は頻繁に、あるいは継続的に気になる発汗を伴う患者です。その程度は、少し湿っている程度から極端に滴り落ちる程度まで様々です。そのため、多汗症は、日常生活、社会的関係、勉強や仕事、生活や感情の制限など、罹患患者の生活の質（QoL）を大幅に損なう可能性があります。人々は多汗症の治療や投薬にシフトするため、治療処置の需要が増加します。これらの要因が市場成長を促進すると予想されます。

上市数の増加が市場成長を牽引すると予想される

多汗症治療用デバイスの上市数の増加が市場成長の原動力になるとみられます。例えば、2022年10月7日、Dermadry社は、手、足、脇の過剰発汗（多汗症）を治療するベストセラーのイオントフォレーシス装置のリニューアルシリーズを発売しました。この機器は、世界的に多汗症に苦しむ何百万人もの人々に適した、シームレスで快適かつ楽な治療体験を提供するために生まれ変わりました。

また、マルホ株式会社は、2022年5月23日、日本で原発性腋窩多汗症治療薬「ラピフォートワイプス 2.5%」を発売しました。有効成分のグリコピロニウムトシル酸塩水和物は、汗腺のアセチルコリン受容体の活性化を阻害することで汗の分泌を抑えます。このように、製品の発売は市場の成長を促進すると予想されます。

治療に伴う副作用が市場成長の妨げになる可能性

経口薬に伴う副作用が市場成長の妨げになると予想されます。一部の錠剤（経口薬）は、汗腺の引き金となる神経をブロックします。これにより、人によっては発汗が減少することがあります。起こりうる副作用には、口の渇き、目のかすみ、膀胱の問題や排尿の合併症、錯乱、めまい、目の眠気や砂のような感じ、光に対する目の過敏症、膨満感の増大、便秘、皮膚の乾燥、心拍の速さなどがあります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 多汗症の有病率の上昇
      • 上市数の増加
    • 抑制要因
      • 治療に伴う高コスト
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • ロシア・ウクライナ戦争の影響分析
  • DMIの見解

第6章 COVID-19分析

第7章 疾患タイプ別

  • 原発性局所性多汗症
  • 二次性全般性多汗症

第8章 治療タイプ別

  • 局所治療
  • ボツリヌス毒素A
  • イオントフォレーシス
  • 外科的治療
  • その他

第9章 エンドユーザー別

  • 病院
  • 外来手術センター
  • その他

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋
  • 中東・アフリカ

第11章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第12章 企業プロファイル

  • LGM Pharma
    • 企業概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な動向
  • GlaxoSmithKline
  • REVANCE AESTHETICS
  • Strides Pharma Science Limited
  • MANUS AKTTEVA BIOPHARMA LLP
  • Dr. August Wolff Gmbh & Co.
  • SLUCARE
  • Kaken Pharmaceutical Co., Ltd.
  • Fengchen Group Co., Ltd
  • Advin Health Care

第13章 付録

目次
Product Code: PH2222

Overview

Global Hyperhidrosis Treatment Devices Market reached US$ 450.2 million in 2022 and is expected to reach US$ 894.1 million by 2030, growing with a CAGR of 4.5% during the forecast period 2023-2030.

Hyperhidrosis is a chronic condition characterized by excessive and uncontrollable sweating. This excessive sweating associated with hyperhidrosis is normally most active in the hands, feet, armpits, and groin because of their relatively high concentration of sweat glands. The increase in the number of treatment approvals and the number of launches of drugs and topical treatments are driving the market growth.

The North America region is expected to hold a significant position in the market share. The Botulinum Toxin A segment holds a significant market share. The increased number of launches and the advantages of the treatment method are expected to hold the segment in the leading position.

Dynamics

Rise in the Prevalence of Hyperhidrosis is Expected to Accelerate the Market Growth

The increase in the prevalence of hyperhidrosis is expected to drive the market growth. For instance, according to the article published in NIH, it is expected that 3% of United States individuals suffer from hyperhidrosis. Primary hyperhidrosis, a specific classification of the disease, primarily affects younger adults aged 18 to 39 years, and it often has a genetic component.

Additionally, in Germany, the prevalence of hyperhidrosis is expected to be 16*3%, including 6*1% of patients with frequent or continuous disturbing sweating. It ranges in severity from being a little bit damp to extreme dripping. Therefore, hyperhidrosis can substantially impair the quality of life (QoL) of affected patients, such as limitations in daily activities, social relationships, study and work, and life and emotional well-being. People shift to the treatment and medication of hyperhidrosis, thus increasing the demand for treatment procedures. These factors are expected to drive the market growth.

Increase in the Number of Launches is Expected to Drive the Market Growth

An increase in the number of launches of devices for the treatment of hypohidrosis is expected to drive market growth. For instance, on October 7, 2022, Dermadry launched a revamped range of its best-selling iontophoresis devices to treat excessive sweating (hyperhidrosis) of the hands, feet, and underarms. This device has been reimagined for a seamless, comfortable, and effortless treatment experience suited for the millions of people affected by hyperhidrosis globally.

Additionally, on May 23, 2022, Maruho Co., Ltd. launched "Rapifort Wipes 2.5%" for the treatment of primary axillary hyperhidrosis in Japan. The active ingredient, glycopyrronium tosilate hydrate, reduces sweat production by blocking the activation of acetylcholine receptors in sweat glands. Thus, the launches of the products are expected to drive the market growth of the market.

Side Effects Associated with the Treatment can Hamper the Market Growth

Side effects associated with oral drugs are expected to hamper the market growth. Some pills (oral medications) block the nerves that trigger sweat glands. This can reduce sweating in some people. Possible side effects include dry mouth, blurred vision, bladder problems and complications with urination, confusion, dizziness, drowsiness or sandy feeling in the eyes, eye sensitivity to light, increased bloated feeling, constipation, dry skin, and rapid heartbeat.

Segment Analysis

The global hyperhidrosis treatment market is segmented based on disease type, treatment type, end-user, and region.

Botulinum Toxin A Segment Holds a Significant Position in the Market Share

Botulinum toxin A is expected to hold a significant position in the market share. The increased number of launches of the Botulinum toxin A (Botox) injections is expected to drive segment growth. For instance, on December 29, 2022, Gufic Biosciences launched the Botulinum toxin type A injection 'Zarbot,' developed and manufactured in collaboration with the United States (US)-based Prime Bio.

Additionally, the advantages of the treatment by injecting Botox over the other types of treatments are expected to hold the segment in a significant position. Botox injections have come to be widely used in managing primary hyperhidrosis when topical treatments have failed. The treatment works by blocking the nerve signals that instruct the sweat glands to become active.

It takes three to four days for the results of Botox injections for hyperhidrosis to become evident. According to the International Hyperhidrosis Society, people who receive Botox injections have found excessive sweating decreases by more than 85%. Thus, the above factors are expected to drive the segment growth.

Geographical Penetration

North America Holds the Largest Market Share in the Global Hyperhidrosis Market

North America holds a dominant force in the hyperhidrosis market. An increase in FDA approvals helps the manufacturers launch the products, and that increases profits for the company. For instance, on April 13, 2023, the US Food and Drug Administration (FDA) cleared Candesant Biomedical's Brella, 3-Minute SweatControl Patch for the treatment of adult patients with primary axillary hyperhidrosis.

Furthermore, on March 27, 2023, Hisamitsu Pharmaceutical Co., Inc. obtained FDA approval for the manufacturing and marketing of APOHIDE Lotion 20% for Japan's primary palmar hyperhidrosis treatment drug. Thus, increasing FDA approvals of the treatments is expected to drive the region's market growth.

Competitive Landscape

The global hyperhidrosis treatment market is fragmented, with the presence of many local and international players. LGM Pharma, GlaxoSmithKline, REVANCE AESTHETICS, Strides Pharma Science Limited, MANUS AKTTEVA BIOPHARMA LLP, Dr. August Wolff Gmbh & Co, SLUCARE, Kaken Pharmaceutical Co., Ltd., Fengchen Group Co., Ltd, and Advin Health Care are the leading Companies with a significant market share.

COVID-19 Impact Analysis

The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide, including the global hyperhidrosis market growth. The COVID-19 pandemic caused disruption in drug manufacturing for non-essential treatments. This has influenced the market growth.

The supply chains have been affected, which affected the product deliveries to the patients, and the availability of the drugs has been reduced. Surgical procedures such as iontophoresis have been delayed and postponed, thus creating a negative impact on market growth. Thus, COVID-19 has influenced the market growth negatively.

By Disease Type

  • Primary Focal Hyperhidrosis
  • Secondary Generalized Hyperhidrosis

By Treatment Type

  • Topical Treatments
  • Botulinum Toxin A
  • Iontophoresis
  • Surgical Treatment
  • Others

By End-User

  • Hospitals
  • Ambulatory Surgical Centers
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Why Purchase the Report?

  • To visualize the global hyperhidrosis treatment market segmentation based on disease type, treatment type, end-user, and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of hyperhidrosis treatment market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global hyperhidrosis treatment market report would provide approximately 61 tables, 58 figures, and 186 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Disease Type
  • 3.2. Snippet by Treatment Type
  • 3.3. Snippet by End-User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rise in the prevalence of hyperhidrosis
      • 4.1.1.2. Increase in the number of launches
    • 4.1.2. Restraints
      • 4.1.2.1. High costs associated with the treatment
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Russia-Ukraine War Impact Analysis
  • 5.6. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Disease Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 7.1.2. Market Attractiveness Index, By Disease Type
  • 7.2. Primary Focal Hyperhidrosis *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Secondary Generalized Hyperhidrosis

8. By Treatment Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 8.1.2. Market Attractiveness Index, By Treatment Type
  • 8.2. Topical Treatments *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Botulinum Toxin A
  • 8.4. Iontophoresis
  • 8.5. Surgical Treatment
  • 8.6. Others

9. By End-User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.1.2. Market Attractiveness Index, By End-User
  • 9.2. Hospitals *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Ambulatory Surgical Centers
  • 9.4. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. UK
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. LGM Pharma *
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. GlaxoSmithKline
  • 12.3. REVANCE AESTHETICS
  • 12.4. Strides Pharma Science Limited
  • 12.5. MANUS AKTTEVA BIOPHARMA LLP
  • 12.6. Dr. August Wolff Gmbh & Co.
  • 12.7. SLUCARE
  • 12.8. Kaken Pharmaceutical Co., Ltd.
  • 12.9. Fengchen Group Co., Ltd
  • 12.10. Advin Health Care

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us